title: Dolutegravir for treatment of HIV: SPRING forwards?
authors.affiliation: Genitourinary and HIV Medicine, Mortimer Market Centre, Central and North West London NHS Foundation Trust, London WC1E 6JB, UK.
authors.forename: Laura J
authors.initials: LJ
authors.lastname: Waters
authors.forename: Tristan J
authors.initials: TJ
authors.lastname: Barber
mesh_terms: D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D019428:HIV Integrase Inhibitors / Q000627:therapeutic use*; D015497:HIV-1; D006575:Heterocyclic Compounds, 3-Ring / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D010078:Oxazines; D010879:Piperazines; D011728:Pyridones; D011760:Pyrrolidinones / Q000627:therapeutic use*; D000068898:Raltegravir Potassium; D000099226:Dolutegravir
chemical_list: D019428:HIV Integrase Inhibitors; D006575:Heterocyclic Compounds, 3-Ring; D010078:Oxazines; D010879:Piperazines; D011728:Pyridones; D011760:Pyrrolidinones; D000068898:Raltegravir Potassium; D000099226:Dolutegravir